IL1B and cancer: Dann et al reported that inhibiting NF-κB activation leads to the repression of the recruitment and activation of immune cells and pro-inflammatory cytokines, such as IL-6 and IL-1β; this repression helps to maintain chronic inflammation and ensure the continuous production of cytokines and growth factors required for the survival and growth of cancer cells [45].